Neuro Metrix, Inc. NURO
We take great care to ensure that the data presented and summarized in this overview for NeuroMetrix, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NURO
View allLatest Institutional Activity in NURO
Top Purchases
Top Sells
About NURO
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Insider Transactions at NURO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 01
2024
|
Shai Gozani President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
42
-0.32%
|
$168
$4.18 P/Share
|
Oct 01
2024
|
Shai Gozani President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
625
+4.5%
|
$2,500
$4.18 P/Share
|
Oct 01
2024
|
Thomas T Higgins Senior Vice President, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-0.47%
|
$192
$4.18 P/Share
|
Oct 01
2024
|
Thomas T Higgins Senior Vice President, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
469
+4.39%
|
$1,876
$4.18 P/Share
|
Aug 02
2024
|
Shai Gozani President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
78
-0.61%
|
$234
$3.46 P/Share
|
Aug 02
2024
|
Shai Gozani President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
636
+4.76%
|
$1,908
$3.46 P/Share
|
Aug 02
2024
|
Thomas T Higgins Senior Vice President, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-0.47%
|
$138
$3.46 P/Share
|
Aug 02
2024
|
Thomas T Higgins Senior Vice President, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
498
+4.84%
|
$1,494
$3.46 P/Share
|
Jul 01
2024
|
Shai Gozani President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-0.63%
|
$231
$3.64 P/Share
|
Jul 01
2024
|
Shai Gozani President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
625
+4.89%
|
$1,875
$3.64 P/Share
|
Jul 01
2024
|
Thomas T Higgins Senior Vice President, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
39
-0.42%
|
$117
$3.64 P/Share
|
Jul 01
2024
|
Thomas T Higgins Senior Vice President, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
469
+4.79%
|
$1,407
$3.64 P/Share
|
May 02
2024
|
Shai Gozani President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
79
-0.68%
|
$316
$4.47 P/Share
|
May 02
2024
|
Shai Gozani President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
636
+5.19%
|
$2,544
$4.47 P/Share
|
May 02
2024
|
Thomas T Higgins Senior Vice President, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-0.94%
|
$336
$4.47 P/Share
|
May 02
2024
|
Thomas T Higgins Senior Vice President, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
498
+5.27%
|
$1,992
$4.47 P/Share
|
Apr 30
2024
|
Nancy E Katz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+41.51%
|
$21,584
$4.37 P/Share
|
Apr 30
2024
|
David Goodman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+41.51%
|
$21,584
$4.37 P/Share
|
Apr 30
2024
|
David Van Avermaete Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+41.52%
|
$21,584
$4.37 P/Share
|
Apr 30
2024
|
Bradley M Fluegel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,396
+38.46%
|
$21,584
$4.37 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 38.4K shares |
---|---|
Grant, award, or other acquisition | 16.4K shares |
Payment of exercise price or tax liability | 1.73K shares |
---|